Navamedic — M&A Activity 2021

Apr 8, 2021

Navamedic ASA: Enters long term distribution agreement for PrecisionBiotics Zenflore® in the Nordics with Novozymes.

Navamedic ASA: Enters long term distribution agreement for PrecisionBiotics Zenflore® in the Nordics with Novozymes.

Oslo, April 8, 2021 - Navamedic ASA (OSE: NAVA) enters exclusive long term

distribution agreement with Novozymes for PrecisionBiotics Zenflore® in the

Nordics. Through this agreement Navamedic strengthens its position within

consumer healthcare and clinically proven probiotics for specific disease areas.

"We are proud to announce the agreement with Novozymes which expands our product

portfolio within probiotics for specific disease areas in the Nordics. The

agreement is an extension of the great collaboration between our two companies

for PrecisionBiotics Alflorex®, which we launched in 2019, and demonstrates the

value of Navamedic's local competence and insight in important disease areas and

consumer needs" says Kathrine Gamborg Andreassen, CEO in Navamedic ASA.

The special 1714-Serenitas® live culture in Zenflore® was discovered and

developed in partnership with scientists and clinicians from one of the world's

leading centres of research on the microbiome and the gut-brain axis, the APC

Microbiome Institute at University College Cork, Ireland. Clinical studies have

demonstrated that Bifidobacterium longum 1714 improves the ability to handle

stressful situations, supports mental performance and combat mental fatigue.

Zenflore® also contains selected Vitamin Bs which contributes to the reduction

of fatigue and to sustain normal psychological ability.

Kathrine Gamborg Andreassen continues: "Navamedic focuses on products within

specialty pharma, medical nutrition and consumer health. Zenflore® strengthens

our position within consumer healthcare wherein we see a great potential for

development of products and categories - like stress and mental health in this

case. The agreement has a term of eight years with automatic renewal and

strengthens our position in the entire Nordic region, which is our most

important home market."

Steve Howson, Head of B2C at Novozymes One Health commented: "We are delighted

to have reached agreement with our colleagues at Navamedic to launch Zenflore®

in the Nordic region. We already have a strong and successful partnership built

on the launch of Alflorex® in Norway, Denmark and Netherlands over the last few

years. We look forward to working with the Navamedic team to bring Zenflore® to

consumers across the region."

PrecisionBiotics Group has for more than 20 years developed products based upon

living bacterial cultures (probiotics) in collaboration with scientists and

clinicians at the APC Microbiome Institute. Commercialised products are

clinically proven in Europe and USA. PrecisionBiotics Group was acquired by the

Danish company NovoZymes A/S in 2020.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality

products, delivered to hospitals and through pharmacies, meeting the specific

needs of patients and consumers by leveraging its highly scalable market access

platform, leading category competence and local knowledge. Navamedic is present

in all the Nordic countries, the Baltics and Benelux, with sales representation

in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on

the Oslo Stock Exchange (ticker: NAVA). For more information, please visit

www.navamedic.com

About Novozymes

Novozymes is the world leader in biological solutions. Together with customers,

partners and the global community, we find biological answers to preserve the

planet's resources and help build better lives. As the world's largest provider

of enzyme and microbial technologies, our bioinnovation enables increased health

and nutritional benefits, higher agricultural yields, improved washing, energy

-efficient production, renewable fuel and many other benefits that we rely on

today and in the future. We call it Rethink Tomorrow. www.novozymes.com